Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 113Neoplasm Metastasis 5Carcinoma, Intraductal, Noninfiltrating 5Polycystic Ovary Syndrome 4Ovarian Neoplasms 4Osteoporosis 4Neoplasms 4Infertility 4Breast Neoplasms, Male 4Arthralgia 4Fallopian Tube Neoplasms 3Triple Negative Breast Neoplasms 2Pain 2Leiomyosarcoma 2Leiomyoma 2Endometrial Neoplasms 2Cystadenocarcinoma, Serous 2Breast Carcinoma In Situ 2Bone Diseases, Metabolic 2Advanced Breast Cancer 2Uterine Neoplasms 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Cysts 1Osteitis Deformans 1Obesity 1Multiple Endocrine Neoplasia Type 1 1Medullary cystic kidney disease 1 1Lymphoma, Non-Hodgkin 1

Interventions

Zoledronic Acid 3Risedronic Acid 3Denosumab 3Vitamin D 2Letrozole 2Calcium 2Nutrition Assessment 1Ibandronic Acid 1Geritol 1Calcium Carbonate 1Aromatase Inhibitors 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Bone Diseases, Metabolic × Letrozole × Clear all
NCT00050011 2014-03-21

Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy

Novartis

Phase 3 Completed
602 enrolled 13 charts
Breast

Bone Diseases, Metabolic, Breast Neoplasms, Osteoporosis

NCT00171340 2012-04-16

Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.

Novartis

Phase 3 Completed
1,065 enrolled 10 charts
Breast

Bone Diseases, Metabolic, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡